Meeting
2023 ASCO Annual Meeting
Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.
Authors
Brian Ko
Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD
Brian Ko , Alice P. Chen , Shivaani Kummar , Murielle Hogu , Larry V. Rubinstein , Naoko Takebe , Richard Piekarz , Elad Sharon , Jan Hendrik Beumer , Deborah Wilsker , Donna Ketchum , Katherine V. Ferry-Galow , Ralph E. Parchment , Julianne L. Holleran , Joshua J. Deppas , Jerry M. Collins , Barry C. Johnson , S. Percy Ivy , James H. Doroshow , Geraldine Helen O'Sullivan Coyne
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Chemotherapy and Antibody-Drug Conjugates
Clinical Trial Registration Number
NCT03030417
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3022)
DOI
10.1200/JCO.2023.41.16_suppl.3022
Abstract #
3022
Poster Bd #
220
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase I study of indenoisoquinolines LMP776 in adults with relapsed solid tumors and lymphomas.
First Author: Geraldine Helen O'Sullivan Coyne
Poster
2023 ASCO Annual Meeting
Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed/refractory solid tumors (JPCS Part A).
First Author: Álvaro Lassaletta
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
Poster
2019 ASCO Annual Meeting
A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
First Author: Nancy Chan